News & Industry Updates

Other Feb 09, 2022

EPICC Peptide Review Article Published – Frontiers In Immunology

The review article, “The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action and In Vivo and...

Read More
Other Jan 05, 2022

ReAlta to Participate At BIO – JP Morgan

Norfolk, VA, January 6th, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is...

Read More
Other Nov 16, 2021

MPO Data Presented at ACR 2021

Myeloperoxidase activity in individuals with Anti-neutrophil cytoplasmic antibodies (ANCA) can be inhibited by RLS-0071 At the 2021 Annual Conference of...

Read More
Other Nov 02, 2021

ReAlta to Participate in Jefferies Healthcare Conference

Norfolk, VA, November 2, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, will...

Read More
Other Oct 12, 2021

ReAlta to Participate in Needham Biotech Forum

Norfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and...

Read More
Other Sep 22, 2021

ReAlta to Participate in Oppenheimer Healthcare Summit

Norfolk, VA, September 22, 2021 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer and John...

Read More
Other Sep 20, 2021

ID Week Conference – Intestinal Necrosis Presentation

ID Week – New Intestinal Necrosis Data Dr. Parvathi Kumar, ReAlta’s Associate Director of Early Clinical Development, will be presenting...

Read More
Press Releases Jun 08, 2021

ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst to Accelerate...

RLS-0071 is in development for treatment of Acute Lung Injury (ALI) and Hypoxic Ischemic Encephalopathy (HIE) Norfolk, VA, June 8,...

Read More
Other Jun 07, 2021

Norfolk startup studying COVID-19 treatment completes $20 million funding round

The Virginian Pilot A Norfolk biotech startup researching treatments for a serious side effect of COVID-19 recently received another funding...

Read More